| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | 0.23 | 3e-12 |
| mRNA | Nilotinib | CTRPv2 | pan-cancer | AAC | 0.22 | 6e-10 |
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | 0.21 | 3e-09 |
| mRNA | ML239 | CTRPv2 | pan-cancer | AAC | 0.2 | 1e-08 |
| mRNA | Imatinib | CTRPv2 | pan-cancer | AAC | 0.19 | 4e-08 |
| mRNA | ruxolitinib | GDSC1000 | pan-cancer | AAC | 0.16 | 6e-07 |
| mRNA | Fumonisin B1 | CTRPv2 | pan-cancer | AAC | 0.18 | 8e-07 |
| mRNA | dexamethasone | CTRPv2 | pan-cancer | AAC | -0.16 | 9e-07 |
| mRNA | compound 1B | CTRPv2 | pan-cancer | AAC | 0.18 | 1e-06 |
| mRNA | BRD-K99006945 | CTRPv2 | pan-cancer | AAC | 0.23 | 6e-06 |